Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Nasal Spray Influenza Vaccine Market?

In recent times, the nasal spray influenza vaccine market has seen swift expansion. It is projected to escalate from $1.31 billion in 2024 to $1.49 billion in 2025, with a compound annual growth rate (CAGR) of 13.2%. The remarkable growth during this pre-existing period can be traced back to factors such as enhanced accessibility of vaccines, increased consciousness about flu prevention measures, intensified emphasis on child vaccination, surge in vaccination rates, and a growing inclination towards vaccines that do not involve needles.

What Growth Rate Is Forecasted for the Nasal Spray Influenza Vaccine Market by 2029?

Expectations are high for swift expansion in the nasal spray influenza vaccine market in the coming years. With a compound annual growth rate (CAGR) of 13.1%, it is anticipated to reach $2.43 billion by 2029. The factors attributed to this projected growth during the forecast period include a rising preference for easier immunization methods, surges in seasonal influenza, amplified government backing and initiatives, anticipated growth in the elderly and high-risk populations, as well as increasing implementation in healthcare environments. Significant trends during the forecast period encompass the progression of vaccine delivery systems, integration of strategies associated with mucosal immunity, advancements in the arena of viral vector platforms and cold-chain technology, and the inclusion of mRNA technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp

Which Key Companies Are Shaping the Future of the Nasal Spray Influenza Vaccine Market?

Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited

Which Factors Are Driving Demand in the Nasal Spray Influenza Vaccine Industry?

The escalating incidence of influenza is forecasted to augment the expansion of the nasal spray influenza vaccine in the future. Influenza is a highly infectious viral infection that principally impacts the respiratory system, leading to symptoms such as fever, cough, sore throat, body discomfort, and fatigue. The escalating incidence of influenza can be largely attributed to the constant genetic alterations of the influenza virus, helping it bypass existing immunity and swiftly spreading among populations. The nasal spray influenza vaccine offers protection against influenza by delivering a debilitated form of the virus directly into the nasal passages, which provokes an immune response where the virus typically infiltrates the body. For example, the UK Health Security Agency, a government agency in the UK, reported in June 2024 that between week 40 of 2022 and week 15 of 2023, 1,681 confirmed influenza-related critical care admissions were accounted for by 108 NHS trusts in England. In contrast, only 182 admissions were reported by 114 trusts in the prior season, which rose to 316 admissions by week 39 of 2022. As a result, the escalating incidence of influenza is fueling the expansion of the nasal spray influenza vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp

How Is the Nasal Spray Influenza Vaccine Market Segmented by Several Divisions?

The nasal spray influenza vaccine market covered in this report is segmented –

1) By Type: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine

2) By Administration Method: Single-Dose Administration, Multi-Dose Administration

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Online Stores, Other Distribution Channels

5) By End User: Healthcare Providers, Individuals, Government Health Departments, Pharmaceutical Companies

Subsegments:

1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV), Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)

2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Subunit Inactivated Vaccine, Adjuvanted Inactivated Vaccine, High-Dose Inactivated Vaccine

What are the Emerging Market Trends Driving the Growth of the Nasal Spray Influenza Vaccine Industry?

Many leading businesses in the nasal spray influenza vaccine market are concentrating on creating novel formulations like live attenuated influenza vaccines. These kinds of vaccines enhance the immune respone and increase patient compliance. A live attenuated influenza vaccine (LAIV), for instance, is a flu shot created from live, weakened flu viruses. It aids in flu prevention by triggering the immune system to generate antibodies. This provides protection without causing illness and provides a more thorough immune response via both local and systemic immunity, heightening the body’s flu-fighting capabilities. In September 2024, AstraZeneca Plc, a pharmaceutical company based in the UK, got authorization from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV). This vaccine can either be self-administered by adults up to 49 years or given by caregivers to kids aged 2-17 years, making it the only flu vaccine in the US approved for self- or caregiver- administration. This authorization was given after comprehensive usability studies showed that people could effectively self-administer this vaccine, with all participants delivering a complete dose as directed.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report

Which Regions Are Driving Growth in the Nasal Spray Influenza Vaccine Market?

North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp

This Report Delivers Insight On:

1. How big is the nasal spray influenza vaccine market, and how is it changing globally?

2. Who are the major companies in the nasal spray influenza vaccine market, and how are they performing?

3. What are the key opportunities and risks in the nasal spray influenza vaccine market right now?

4. Which products or customer segments are growing the most in the nasal spray influenza vaccine market?

5. What factors are helping or slowing down the growth of the nasal spray influenza vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model